CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.
Patrizia Cavazzoni and Peter Marks continue to trumpet the benefits of the US Food and Drug Administration’s hybrid workplace, but a concern lingers that the momentum could lost.
Since the FDA moved to a system allowing most employees to work from home or the office at the beginning...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
